Azucena Aldaz

1.2k total citations
50 papers, 772 citations indexed

About

Azucena Aldaz is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Azucena Aldaz has authored 50 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pediatrics, Perinatology and Child Health and 11 papers in Pharmacology. Recurrent topics in Azucena Aldaz's work include Antibiotics Pharmacokinetics and Efficacy (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Pharmacological Effects and Toxicity Studies (7 papers). Azucena Aldaz is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Pharmacological Effects and Toxicity Studies (7 papers). Azucena Aldaz collaborates with scholars based in Spain, United States and Tanzania. Azucena Aldaz's co-authors include J. Giráldez, Ana Ortega, Emiliano Calvo, C. Viteri, María J. Blanco‐Prieto, Luis Sierrasesúmaga, Patrick Couvreur, Carlos Rodríguez‐Nogales, Ilse Van Vlaenderen and B Poulsen Nautrup and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and ACS Nano.

In The Last Decade

Azucena Aldaz

47 papers receiving 744 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Azucena Aldaz Spain 18 211 162 122 118 116 50 772
Helena Colom Spain 19 170 0.8× 236 1.5× 241 2.0× 85 0.7× 119 1.0× 86 1.2k
Andrew K. Trull United Kingdom 23 111 0.5× 240 1.5× 178 1.5× 46 0.4× 117 1.0× 53 1.4k
Ignacio Segarra Spain 16 120 0.6× 129 0.8× 44 0.4× 64 0.5× 51 0.4× 43 740
Peter Matzneller Austria 17 197 0.9× 144 0.9× 109 0.9× 34 0.3× 280 2.4× 49 898
Averell H. Sherker United States 26 204 1.0× 123 0.8× 67 0.5× 175 1.5× 39 0.3× 47 1.6k
Thomas Mercier Switzerland 17 73 0.3× 136 0.8× 61 0.5× 187 1.6× 184 1.6× 33 685
I Bekersky United States 17 149 0.7× 185 1.1× 128 1.0× 54 0.5× 123 1.1× 37 814
Michael Seiberling Switzerland 21 221 1.0× 309 1.9× 83 0.7× 59 0.5× 93 0.8× 45 1.6k
Kevin Krudys United States 11 69 0.3× 202 1.2× 192 1.6× 31 0.3× 100 0.9× 20 792
Karin Cederbrant Sweden 18 108 0.5× 148 0.9× 25 0.2× 101 0.9× 185 1.6× 34 1.1k

Countries citing papers authored by Azucena Aldaz

Since Specialization
Citations

This map shows the geographic impact of Azucena Aldaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Azucena Aldaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Azucena Aldaz more than expected).

Fields of papers citing papers by Azucena Aldaz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Azucena Aldaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Azucena Aldaz. The network helps show where Azucena Aldaz may publish in the future.

Co-authorship network of co-authors of Azucena Aldaz

This figure shows the co-authorship network connecting the top 25 collaborators of Azucena Aldaz. A scholar is included among the top collaborators of Azucena Aldaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Azucena Aldaz. Azucena Aldaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vives, Marc, et al.. (2024). Use of vancomycin and acute kidney injury in critically ill patients with sepsis or septic shock: A retrospective observational cohort study. Revista Española de Anestesiología y Reanimación (English Edition). 72(2). 501657–501657.
2.
3.
Vilalta, A., Azucena Aldaz, Á. Chopitea, et al.. (2023). Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma. Pancreatology. 23(4). 411–419. 1 indexed citations
4.
Aldaz, Azucena, et al.. (2020). Effectiveness of Pharmacokinetic/Pharmacodynamic-Guided Meropenem Treatment in Critically Ill Patients: A Comparative Cohort Study. Therapeutic Drug Monitoring. 43(2). 256–263. 8 indexed citations
5.
Leache, Leire, et al.. (2019). Effectiveness of adjunctive nebulized antibiotics in critically ill patients with respiratory tract infections. European Journal of Clinical Microbiology & Infectious Diseases. 39(2). 361–368. 3 indexed citations
6.
Aldaz, Azucena, et al.. (2019). Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. Journal of Pharmacological Sciences. 140(1). 20–25. 33 indexed citations
7.
Leache, Leire, et al.. (2019). 4CPS-058 Avoid simultaneus prescription between linezolid and voriconazole: pharmacokinetic study. Section 4: Clinical pharmacy services. A94.2–A95. 1 indexed citations
8.
Aldaz, Azucena, et al.. (2019). Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. European Journal of Clinical Pharmacology. 75(4). 529–542. 8 indexed citations
9.
Chaccour, Carlos, Kija R Ng’habi, Gloria Abizanda, et al.. (2018). Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a slow-release ivermectin implant formulation. Parasites & Vectors. 11(1). 287–287. 46 indexed citations
10.
Leache, Leire, et al.. (2018). Evidence of clinical and economic impact of pharmacist interventions related to antimicrobials in the hospital setting. European Journal of Clinical Microbiology & Infectious Diseases. 37(5). 799–822. 8 indexed citations
11.
Rodríguez‐Nogales, Carlos, et al.. (2018). Nanomedicines for Pediatric Cancers. ACS Nano. 12(8). 7482–7496. 64 indexed citations
12.
Ortega, Ana, et al.. (2018). Influence of Sex, Age, and Weight on Levetiracetam Pharmacokinetics. Therapeutic Drug Monitoring. 40(5). 628–634. 13 indexed citations
13.
Chaccour, Carlos, Felix Hammann, Gloria Abizanda, et al.. (2017). Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae. Scientific Reports. 7(1). 8535–8535. 25 indexed citations
14.
Garrido, Pilar, Azucena Aldaz, Miguel Ángel Calleja, et al.. (2017). Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH.. SHILAP Revista de lepidopterología. 41(6). 688–691. 4 indexed citations
15.
Aldaz, Azucena, et al.. (2011). Monitorización farmacocinética de antiepilépticos. Farmacia Hospitalaria. 35(6). 326–339. 16 indexed citations
16.
Aldaz, Azucena, et al.. (2010). Validation of an LC Method for Therapeutic Drug Monitoring of Voriconazole in Patients. Journal of Bioanalysis & Biomedicine. 2(2). 4 indexed citations
17.
18.
Aldaz, Azucena, et al.. (2004). Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection. Journal of Chromatography B. 809(1). 51–58. 52 indexed citations
19.
Aldaz, Azucena, et al.. (2003). Methotrexate pharmacokinetics and survival in osteosarcoma. Pediatric Blood & Cancer. 42(1). 52–58. 30 indexed citations
20.
Aldaz, Azucena, et al.. (2000). Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. Journal of Chromatography B Biomedical Sciences and Applications. 740(2). 159–168. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helena Colom Breakdown of academic impact, for papers by Andrew K. Trull Breakdown of academic impact, for papers by Ignacio Segarra Breakdown of academic impact, for papers by Peter Matzneller Breakdown of academic impact, for papers by Averell H. Sherker Breakdown of academic impact, for papers by Thomas Mercier Breakdown of academic impact, for papers by I Bekersky Breakdown of academic impact, for papers by Michael Seiberling Breakdown of academic impact, for papers by Kevin Krudys Breakdown of academic impact, for papers by Karin Cederbrant
Rankless by CCL
2026